SCHEMBL4326548

SCHEMBL4326548

COC(=O)CC(N)c1cccc(I)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 2/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
F2 P00734 7/20 0.41
F10 P00742 7/20 0.41
PRSS1 P07477 6/20 0.40
SLC7A5 Q01650 1/20 0.40
ALDH1A1 P00352 1/20 0.39
ANPEP P15144 1/20 0.39
ENPEP Q07075 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
KCNA5 P22460 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
TACR3 P29371 1/20 0.36
TACR1 P25103 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20546560 0.85 F10 (0.42) SLC6A3KMT2ASMN1; SMN2F2F10
SCHEMBL3580558 0.83 KYNU (0.47) SLC6A3KMT2ASMN1; SMN2F2F10
SCHEMBL18516122 0.83 AOC3 (0.43) KMT2ASMN1; SMN2F2F10PRSS1
SCHEMBL6495546 0.83 CPN1 (0.45) KMT2ASMN1; SMN2F2F10PRSS1
SCHEMBL5720896 0.83 KMT2A (0.38) SLC6A3KMT2ASMN1; SMN2F2F10
SCHEMBL24036585 0.82 PNP (0.47) KMT2ASMN1; SMN2ALDH1A1
SCHEMBL21459309 0.82 KCNA5 (0.49) KMT2ASMN1; SMN2F2F10PRSS1
SCHEMBL6185468 0.82 L3MBTL1 (0.58) KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL8296972 0.82 KCNA5 (0.49) KMT2ASMN1; SMN2F2F10PRSS1
SCHEMBL7422382 0.82 HDAC4 (0.46) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230095637-A1 Heterodimers of Glutamic Acid CITIZENS BANK, N.A. 2023-03-30 US disclosed
EP-4023624-A1 HETERODIMERS OF GLUTAMIC ACID Molecular Insight Pharmaceuticals, Inc. (US) 2022-07-06 EP disclosed
EP-3699162-B1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARM INC (US) 2022-06-29 EP disclosed
EP-3699162-B1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARM INC (US) 2022-06-29 EP disclosed
US-20210246103-A1 HETERODIMERS OF GLUTAMIC ACID CITIZENS BANK, N.A. 2021-08-12 US disclosed
US-20210246103-A1 HETERODIMERS OF GLUTAMIC ACID CITIZENS BANK, N.A. 2021-08-12 US disclosed
US-20210070695-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2021-03-11 US disclosed
US-20210070696-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2021-03-11 US disclosed
US-20210070696-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2021-03-11 US disclosed
US-20210070695-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2021-03-11 US disclosed
US-20120269726-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2012-10-25 US disclosed
US-20120269726-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2012-10-25 US disclosed
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
EP-2097111-A2 HETERODIMERS OF GLUTAMIC ACID Molecular Insight Pharmaceuticals, Inc. (US) 2009-09-09 EP disclosed
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2008-08-14 US disclosed
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2008-08-14 US disclosed
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2008-08-14 US disclosed
WO-2008058192-A2 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2008-05-15 WO disclosed
WO-2008058192-A2 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070695-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS SLC6A3 438/4885KMT2A 2413/4885SMN1; SMN2 3022/4885
US-20120269726-A1 Heterodimers of Glutamic Acid DDO, GLUL, ASNS SLC6A3 449/4885KMT2A 2428/4885SMN1; SMN2 3020/4885
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS SLC6A3 438/4885KMT2A 2413/4885SMN1; SMN2 3022/4885
US-20210070696-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS SLC6A3 440/4885KMT2A 2402/4885SMN1; SMN2 2993/4885
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS SLC6A3 438/4885KMT2A 2413/4885SMN1; SMN2 3022/4885
US-20230095637-A1 Heterodimers of Glutamic Acid DDO, GLUL, ASNS SLC6A3 429/4885KMT2A 2377/4885SMN1; SMN2 3017/4885
US-20210246103-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS SLC6A3 438/4885KMT2A 2413/4885SMN1; SMN2 3022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.